Verdu E, Viani F, Armstrong D, Fraser R, Siegrist H H, Pignatelli B, Idström J P, Cederberg C, Blum A L, Fried M
Division of Gastroenterology, Centre Hospitalier, University Vaudois (CHUV/PMU), Lausanne, Switzerland.
Gut. 1994 Apr;35(4):455-60. doi: 10.1136/gut.35.4.455.
Previous studies have suggested that profound inhibition of gastric acid secretion may increase exposure to potentially carcinogenic N-nitroso compounds. The aim of this study was to find out if the proton pump inhibitor omeprazole (20 mg daily) is associated with increased concentrations of potentially carcinogenic N-nitroso compounds in gastric juice. The volume of gastric contents, number of bacteria, and concentrations of nitrates, nitrites, and N-nitroso compounds was determined in gastric aspirates obtained after an overnight fast in 14 healthy volunteers (7M:7F) after one week of treatment with placebo, and one and two weeks' treatment with omeprazole. Median bacterial concentrations were 1.0 x 10(4) (range 5.0 x 10(3)-5.0 x 10(6)) colony forming units (CFU)/ml after one weeks' treatment with placebo and increased significantly to 4.0 x 10(5) (0-3.3 x 10(7)) CFU/ml after two weeks' treatment with omeprazole (p < 0.05). A similar increase was seen in the concentration of nitrate reducing bacteria. There was no difference in the volume of gastric aspirates after treatment with omeprazole when compared with placebo (65 (29-155) ml v 42 (19-194) ml). The concentration of N-nitroso compounds was 0.13 (0-1.0) mumol/l after two weeks of omeprazole, which was not significantly different from that seen with placebo (0.15 (0-0.61) mumol/l). There was also no increase in the concentrations of nitrates or nitrites. It is concluded that omeprazole (20 mg once daily) for two weeks in healthy volunteers is associated with gastric bacterial proliferation but does not increase concentrations of N-nitroso compounds.
先前的研究表明,胃酸分泌受到深度抑制可能会增加接触潜在致癌性N-亚硝基化合物的风险。本研究的目的是探究质子泵抑制剂奥美拉唑(每日20毫克)是否与胃液中潜在致癌性N-亚硝基化合物浓度升高有关。在14名健康志愿者(7名男性:7名女性)禁食过夜后获取胃抽吸物,分别测定在服用安慰剂一周后、服用奥美拉唑一周和两周后的胃内容物体积、细菌数量以及硝酸盐、亚硝酸盐和N-亚硝基化合物的浓度。服用安慰剂一周后,细菌浓度中位数为1.0×10⁴(范围为5.0×10³ - 5.0×10⁶)菌落形成单位(CFU)/毫升,服用奥美拉唑两周后显著增加至4.0×10⁵(0 - 3.3×10⁷)CFU/毫升(p < 0.05)。硝酸盐还原菌的浓度也有类似的增加。与安慰剂相比,服用奥美拉唑后胃抽吸物的体积没有差异(65(29 - 155)毫升对42(19 - 194)毫升)。服用奥美拉唑两周后,N-亚硝基化合物的浓度为0.13(0 - 1.0)微摩尔/升,与服用安慰剂时(0.15(0 - 0.61)微摩尔/升)无显著差异。硝酸盐或亚硝酸盐的浓度也没有增加。结论是,健康志愿者每日一次服用20毫克奥美拉唑两周与胃细菌增殖有关,但不会增加N-亚硝基化合物的浓度。